Raptiva PML Side Effects Lawsuit
Raptiva PML Side Effect Lawsuits. Raptiva, a drug used to treat psoriasis, has been associated with a serious viral brain disease called progressive multifocal leukoencephalopathy (Progressive Multifocal Leukoencephalopathy PML). Progressive Multifocal Leukoencephalopathy PML is a rare virus that affects the central nervous system … [Read more...] about Raptiva PML Side Effects Lawsuit
Raptiva Side Effects May Result In Skin Cancer Lawsuits
Raptiva Side Effects Cause Skin Cancer. Raptiva (Generic: Efalizumab) is a humanized monoclonal antibody targeted toward the hyperproliferative pathology of psoriasis. As an immunosuppressive agent, Raptiva "has the ability to enhance the threat of infection and reactivate latent, chronic infections," the label cautions. … [Read more...] about Raptiva Side Effects May Result In Skin Cancer Lawsuits
Raptiva Not Available in Canada
Raptiva No Longer Available. Raptiva has been pulled from the market in Canada because of its association with an often-fatal brain infection called progressive multifocal leukoencephalitis (PML). The suspension of Raptiva sales in Canada is part of a global withdrawal of the drug. Raptiva works by blocking the activation of … [Read more...] about Raptiva Not Available in Canada
Raptiva Pulled from Market Following Deaths
Raptiva Pulled from U.S. Market. Raptiva, an injectable drug used to treat moderate to severe plaque psoriasis, is being withdrawn from the U.S. market. According to Genentech, Raptiva has been associated with progressive multifocal leukoencephalopathy (PML), a serious and almost always fatal brain infection caused by a … [Read more...] about Raptiva Pulled from Market Following Deaths
Raptiva Sales Suspension Recommended In Europe
Raptiva Sales Suspension. On the same day U.S. regulators warned that the psoriasis drug Raptiva had been linked to three fatal case of a rare brain infection, their counterparts in the European Union have recommended sales of the drug be suspended. In a statement, advisers to the European Medicines Agency (EMEA) said that in … [Read more...] about Raptiva Sales Suspension Recommended In Europe
New Safety Warning for Raptiva
Psoriasis Drug Raptiva New Safety Warnings. The FDA and Genetech have issued a new safety warning for the psoriasis drug Raptiva which addresses serious potential side effects of the drug including: immune-mediated hemolytic anemia, in which the immunes system mistakes red blood cells for foreign cells and attacks them; and … [Read more...] about New Safety Warning for Raptiva
Raptiva Label to Include Hemolytic Anemia Warning
Raptiva May Cause Hemolytic Anemia. The FDA announced today new warnings on the Genentech psoriasis drug Raptiva (efalizumab) following reports of four cases of hemolytic anemia diagnosed four to six months after patients started on the monoclonal antibody. Two of the cases occurred in clinical trials of Raptiva, and two … [Read more...] about Raptiva Label to Include Hemolytic Anemia Warning
